Share Price:

APNASPENAspen Pharmacare Hldgs1967273 (0.37%)

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.

2014 Anti-retroviral tender results

Following the announcement of the Anti-Retroviral (ARV) Tender results by the South African National Treasury Department, Aspen Pharmacare Holdings Limited is pleased to announce that its South African operating company (Pharmacare Limited t/a Aspen Pharmacare) has been successful in winning a number of key products in the tender Aspen’s award included 25% of the Fixed… Continue reading 2014 Anti-retroviral tender results

Aspen’s world class PE site manufactures and exports pharmaceutical products for global markets

Port Elizabeth. The Minister of Trade and Industry, Dr Rob Davies today visited the Aspen Pharmacare manufacturing site in Port Elizabeth, Eastern Cape. The purpose of the visit was to engage on the future direction and orientation of the Pharmaceutical Industry in South Africa. The visit was also for Minister Davies to see first-hand the… Continue reading Aspen’s world class PE site manufactures and exports pharmaceutical products for global markets

Aspen acquires a stake in an IMF production facility in New Zealand

Aspen Holdings is pleased to announce that it has concluded a transaction to acquire a 50% shareholding in New Zealand New Milk Limited (“NZNM”), a producer of infant milk formula in Auckland, New Zealand. In terms of a supply agreement concluded between Aspen Global Incorporated and NZNM, long-term supply of infant milk formula for distribution… Continue reading Aspen acquires a stake in an IMF production facility in New Zealand

Stephen Saad’s Aspen: From JSE newcomer to R150bn valuation in 16 years

In 1998, Stephen Saad and Gus Attridge took their ambitions public through the reverse takeover by their year-old business into JSE-listed Medhold. A year later they pulled off a R2.4bn hostile takeover of the well resourced but poorly managed SA Druggists. And the rest is history. Now a multinational corporation, last week Aspen delivered another sparkling… Continue reading Stephen Saad’s Aspen: From JSE newcomer to R150bn valuation in 16 years

Aspen’s revenue soars by 53% to R29.5 billion

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the fifth largest generic company in the world and Africa’s largest pharmaceutical manufacturer, has announced excellent results for the year ended 30 June 2014. GROUP PERFORMANCE Revenue increased by 53% to R29.5 billion. Operating profit rose by 47% to R7.4 billion. Normalised headline earnings, being… Continue reading Aspen’s revenue soars by 53% to R29.5 billion

Honorary Doctor of Commerce Degree conferred on Stephen Saad

[vimeo id=”91664323″ align=”center” aspect_ratio=”16:9″] Port Elizabeth – The Nelson Mandela Metropolitan University (NMMU) today conferred the degree of Doctor of Commerce (honoris causa) on Stephen Saad, Aspen Group Co-Founder and Chief Executive.Chancellor of the NMMU, Santie Botha said, ‘’It is an honour for NMMU to confer this honorary degree on Stephen Saad. His vision and… Continue reading Honorary Doctor of Commerce Degree conferred on Stephen Saad

Aspen’s half-year revenue increases to R12 billion

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the ninth largest generic company in the world and Africa’s largest pharmaceutical manufacturer, has announced excellent results for the six months ended 31 December 2013. Group Performance Revenue increased by 33% to R12.0 billion. Operating profit improved by 16% to R2.9 billion after absorbing transaction… Continue reading Aspen’s half-year revenue increases to R12 billion

Aspen’s growth formula

On a recent holiday to Disney World with his family, Aspen Pharmacare CE Stephen Saad wandered into a pharmacy while his children enjoyed the rides. On a shelf he found Murine Clear Eyes, the eye drops made at Aspen’s Port Elizabeth plant. “About 2m-3m packs a month are sold around the world but it was… Continue reading Aspen’s growth formula

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.